Acrongenomics Inc. Expanding its Vision of Nanobiotechnology and Molecular Diagnostics.

MONTREAL -- Acrongenomics Inc.'s (OTCBB:AGNM) skillful scientific team is making substantial progress to challenge the environment of Nanobiotechnology by transforming its existing product Ep-CAM Detection Kit(TM), for the detection of epithelial cancer, to a new commercial application for the global molecular diagnostic market.

Nanobiotechnology is a fusion of physical sciences, biology, molecular engineering, chemistry and biotechnology. This field is beginning to generate substantial new insights into how biological systems function and holds much promise of advance in pharmaceuticals and healthcare alike.

Although a relatively new field, the global market for in-vitro diagnostic (IVD) tests is finally showing signs of life, thanks in large part to the application of new technologies to traditional IVD areas. According to a study released by Kalorama Information, and available at MarketResearch.com, sales of IVD products will exceed $28.5 billion US by 2005 and will continue a healthy growth curve for the foreseeable future. Further, D&MD's Nanobiotechnology Briefing states the overall market impact of nanobiotech applications is projected to reach $300 billion US within the next 12 years.

Acrongenomics Inc. is a biotechnology company specializing in the development and marketing of innovative molecular diagnostic solutions, with the goal of providing physicians and researchers superior tools to diagnose and treat various diseases.

Important Information About Forward-Looking Statements 

All statements in this news release that are other than statements of historical facts are forward-looking statements which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates", "believes", "could", "expects", "intends", "may", "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.

A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions.

For further information concerning risks and uncertainties that may affect our future results, please review the disclosures contained in our latest filings with the SEC, including our most recent annual report on Form 10-KSB, and subsequent quarterly reports on Form 10-QSB. Other than as required by federal securities laws, we undertake no obligation to publicly update or revise any of our forward-looking statements, whether as a result of changed circumstances, new information, future events, or for any other reason occurring after the date of this news release.